Thyrotropin Alfa

Evidence Level: L5

Predicted Indications: 9

Thyrotropin Alfa

Pharmacist Assessment Report

Thyrotropin alfa: From Thyroid Diagnostic/Adjunctive Use to Migraine Disorder

One-Sentence Summary

Thyrotropin alfa is recombinant human thyroid-stimulating hormone (TSH), marketed in Australia as Thyrogen; no approved indication text was available in the data compiled for this report. The TxGNN model predicts it may be effective for migraine disorder, but there are 0 clinical trials and 0 publications supporting this direction, so the prediction rests on model output alone.

Quick Overview

Item	Content
Original Indication	Not available in the data compiled for this report
Predicted New Indication	Migraine disorder
TxGNN Prediction Score	0.9998
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the compiled data. Thyrotropin alfa is a recombinant form of human TSH that acts on TSH receptors in thyroid tissue.

There is no established mechanistic link between TSH receptor stimulation and migraine. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. Any link to migraine is speculative.

The other top-ranked predictions are not independent support. Migraine with brainstem aura, and migraine with or without aura (susceptibility), are closely related to the parent migraine prediction. Several others (Raynaud disease, pulmonary hypertension, postural orthostatic tachycardia syndrome) have only loose associations with thyroid status, not with TSH administration. Hyperthyroidism scored highly but is biologically contradictory, since TSH stimulation would be expected to worsen it. It should be treated as a warning signal, not a candidate.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 2700D	Thyrogen	Powder for injection 0.9 mg, 2	Not available in the compiled data

Safety Considerations

Drug Interactions: 45 potential interactions were identified, all graded Moderate in the DDInter database. The 20 listed in the compiled data are all glucose-lowering agents, including:

Biguanides and sulfonylureas: metformin, chlorpropamide, glimepiride, glipizide, glyburide, acetohexamide
Insulins: human insulin and insulin aspart (including aspart protamine)
GLP-1 receptor agonists: albiglutide, dulaglutide, exenatide, semaglutide
DPP-4 inhibitors: alogliptin, saxagliptin
SGLT2 inhibitors: canagliflozin, dapagliflozin, empagliflozin, ertugliflozin
Alpha-glucosidase inhibitor: acarbose

Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.

Mechanism-based concerns noted in the prediction analysis: thyrotropin alfa can transiently raise thyroid hormone levels and may cause tachycardia. This is relevant to several of the predicted cardiovascular indications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is supported only by the TxGNN model (Evidence Level L5). There are no clinical trials or publications, and no plausible mechanistic link between TSH receptor agonism and migraine. Safety information from the product label has not been reviewed.

To proceed, the following is needed:

Review of the TGA-approved Product Information (PI) for warnings, contraindications and approved indications
Mechanism of action data (for example, from DrugBank)
A biological rationale connecting TSH signalling to migraine, supported by preclinical or observational evidence
Confirmation of route and dosing feasibility (the product is an injectable powder for diagnostic or adjunctive use)
A cardiovascular safety assessment, given transient thyroid hormone elevation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.